UNITED THERAPEUTICS Corp

(c)Trading Plans

On October 31, 2025, James Edgemond, Chief Financial Officer and Treasurer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 268,750 stock options and sell the shares of common stock received, subject to certain conditions.

On November 4, 2025, Judy Olian, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 800 shares of our common stock, subject to certain conditions.

On November 7, 2025, Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 1,734,410 stock options and sell the shares of our common stock received, subject to certain conditions. These transactions would commence no earlier than March 2, 2026, and end no later than December 31, 2026, ahead of the anticipated expiration date of these options, which is March 15, 2027. The 1,734,410 stock options covered by this trading plan include options that will be owned by a trust of which Dr. Rothblatt was settlor and in which she has a pecuniary interest.

On December 18, 2025, Christopher Patusky, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 4,910 stock options and sell the shares of common stock received, subject to certain conditions.

During the three months ended December 31, 2025, no director or Section 16 officer terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).